Roche to acquire InterMune Inc. for $8.3 Billion

Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune�s closing price on 22 August 2014 and a premium of 63% to InterMune�s unaffected closing price on 12 August 2014. The merger agreement has been approved by the boards of InterMune and Roche.The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. InterMune�s lead medicine pirfenidone is approved for idiopathic pulmonary fibrosis (IPF) in the EU and Canada and under regulatory review in the United States.